Search Technologies

The National Cancer Institute (NCI) seeks licensees for a library of cell lines stably expressing common tumor-specific antigens and human leukocyte antigens (HLAs) that can be used to identify, isolate, and expand tumor-reactive T cells.

Scientists at the National Cancer Institute (NCI) developed an engineered bacteriophage lambda () vector for displaying antigens to be used as a vaccine in treatment of cancers and infectious diseases. The NCI seeks licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E7. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.

Researchers at the National Cancer Institute (NCI) developed novel molecular nanotags for single biological nanoparticle detection, resolution, and sorting, by flow cytometry. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations to further advance this technology with extremely broad biomedical, biodefense, industrial, environmental, and other applications.

Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.

Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.

Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.

Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.

The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.